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Abstract: Drug delivery to the neonatal and premature pediatric populations is very 
challenging. This research assessed the potential of delivering midazolam by transdermal 
iontophoresis as an alternative strategy in pediatric therapy. In vitro experiments used intact 
and tape-stripped porcine skin as models for the skin barrier function of full-term and 
premature newborns, respectively. Midazolam transdermal transport was significantly 
enhanced by applying higher currents, increasing the formulation pH, and optimizing the 
drug’s mole fraction in the vehicle. When the skin barrier was decreased to half of its baseline 
competence, the passive permeation of midazolam increased by approximately 60-fold; and 
complete stratum corneum removal led to an additional 20-fold enhancement in permeation. 
Iontophoresis retained control of the drug transport trough partially compromised skin. 
However, a very high passive contribution undermined the iontophoretic control when the 
barrier was fully compromised. Overall, midazolam delivery could be rate-controlled by 
iontophoresis in most circumstances, and therapeutically useful fluxes could be achieved.  
 
Keywords: midazolam, pediatric drug delivery, iontophoresis, passive diffusion, 
transdermal drug delivery, skin barrier function.  
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1. Introduction 
 Midazolam, a short acting benzodiazepine, is used in pediatric medicine to treat status 
epilepticus and febrile convulsions, for conscious sedation for procedures, induction of 
anesthesia, premedication and in intensive care where continuous sedation is an integral part 
in patient treatment [1]. The drug is also used in infants and premature neonates and has been 
administered by various routes, including intravenous, oral, rectal, buccal and nasal. 
 Midazolam (MW = 325.8 as free base, 362.3 as HCl salt) is a lipophilic (log P = 4.33) 
weak base (pKa = 6.15) [2,3] (structure shown in Supplementary Material). An extensive first 
pass metabolism results in low oral bioavailability (15 – 30%) [4]. The drug has a short half-
life of ~2 hours (although somewhat longer in neonates) [5] meaning that a sustained 
therapeutic effect requires frequent dosing. The oral solution has a bitter taste so intravenous 
administration is the most common approach when treating infants and children. There are, 
in addition, biopharmaceutical challenges with midazolam, such as its very poor aqueous 
solubility at pH > 5, and its incompatibility with certain drugs (e.g., ranitidine and furosemide) 
and with parenteral nutrition [6-9].  As a consequence, a separate intravenous line for 
midazolam is often necessary and this is self-evidently onerous for young pediatric patients. 
In addition, because of the need for continuous infusion of the drug to ensure consistent 
sedative effects over relatively long periods, scarring at the injection site is another problem.  
Rectal or nasal administration have been tried as alternatives to intravenous delivery but not 
proven useful: rectal administration has resulted in low and inconsistent absorption [4, 10], 
and the nasal route has been associated with significant mucosal irritation [1, 11].  
 Iontophoresis expands the benefits of the transdermal route of administration 
(avoidance of first pass effect, ease of access, and improved patients’ convenience) to drugs 
the physicochemical properties of which make them poor candidates for passive skin delivery 
(charged and polar drugs for example) [12]. Further, iontophoresis is a controlled drug 
delivery technique providing transdermal fluxes directly controlled by the intensity of current 
applied. This allows dose individualization and pulsed delivery profiles. Finally, transdermal 
iontophoretic devices have been approved for paediatric patients, both for drug delivery 
(LidoSite®) and non-invasive glucose sampling (GlucoWatch Biographer®) [12-14]. To provide 
a viable, alternative administration route for midazolam, transdermal iontophoresis must 
mirror the dosing rates achieved by intravenous infusion. For continuous sedation in 
paediatric intensive care, the recommended regimens are: (a) premature neonates of 
gestational age less than 32 weeks, 60 µg/kg/h for 24 hours then reduced to 30 µg/kg/h to be 
adjusted according to response for a maximum 4 days; (b) neonates of more than 32 weeks 
gestational age and infants 1-5 months, 60 µg/kg/h adjusted according to response; (c) Older 
than 6 months, a loading dose of 50 – 200 µg/kg as a slow intravenous injection if required, 
followed by continuous infusion of 30 – 120 µg/kg/h adjusted according to response [1]. 
 The neonatal skin barrier function is close to that of adults by ~35 weeks of gestation 
[15]. However, for very premature infants (i.e., less than 34 weeks gestation), the stratum 
corneum is incompletely formed and barrier function is noticeably impaired [16, 17] as shown 
clearly by measurements of the rate of transepidermal water loss (TEWL) [18-21]. A lower 
barrier function is shown by elevated TEWL. As the developing skin barrier matures, TEWL 
decreases until a constant value is achieved at which point the skin barrier function is fully 
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established. Among other critical issues, the immature barrier of premature neonates of 
shorter gestational age is more permeable to drug transport than intact skin, suggesting an 
opportunity for transdermal delivery [22] (as has been reported previously for theophylline 
and caffeine [23-24]) and for potential toxicity due to unwanted exposure (hexachlorophene) 
[22]. 
 Exploring the feasibility of a drug candidate for transdermal delivery faces two 
particular challenges: (a) excised skin from children (and especially very young infants) is 
difficult, if not impossible to obtain; and, (b) to assess a drug’s skin permeation in the 
paediatric population demands a spectrum of skin membranes of different levels of barrier 
function so as to mimic those encountered in premature neonates and full-term infants. The 
first challenge has been resolved by the use of porcine skin, which is now a well-accepted 
model for human counterpart [25-27]. The second has been addressed by published research 
demonstrating that pig skin, from which the SC has been differentially tape-stripped to 
provide various degrees of barrier compromise (as determined by TEWL measurements), is a 
useful in vitro model for the premature neonatal skin at different levels of maturation [28].  
 The objective of this study was to investigate, using the porcine skin model, the 
feasibility of delivering midazolam by transdermal iontophoresis. First, several variables were 
examined to maximize the iontophoretic electrotransport of midazolam. Second, transdermal 
delivery of midazolam was assessed across skin barriers from which the SC was stripped to 
different extents thereby modelling the less resistant skin of premature babies.  
2. Materials and Methods  
2.1 Chemicals 
 Midazolam hydrochloride was obtained from Apin Chemicals (Oxford, UK), silver 
(Ag) wire (99.99%), silver chloride (AgCl, 99.999%), and sodium hydroxide (NaOH) pellets 
were purchased from Sigma Aldrich (Gillingham, UK). Sodium chloride (NaCl), citric acid 
monohydrate, trisodium citrate dehydrate, disodium hydrogen phosphate, potassium 
dihydrogen phosphate, and phosphoric acid (85 %) were obtained from Acros (Geel, 
Belgium). Acetonitrile and hydrochloric acid (HCl) were provided by Fisher Scientific 
(Loughborough, UK). All reagents were at least analytical grade and highly purified deionised 
water (resistivity ≥ 18.2 MΩ.cm, Barnsted Nanopure DiamondTM, Dubuque, IA) was used for 
the preparation of all solutions. 
2.2 Skin 
 Skin preparation has been described elsewhere [26]. Fresh (dorsal) pig skin was 
acquired from a local abattoir.  The tissue was cleaned in cold water and subsequently 
refrigerated until the following day. The skin was then cut into 20 x 10 cm2 pieces and 
dermatomed (Zimmer™ Electric Dermatome, Dover, Ohio) to a thickness of 750 µm. The skin 
samples were individually wrapped in Parafilm™, and frozen (-20°C) until use. Before 
beginning the permeation experiment, the skin was brought to room temperature over a 
period of ~30 minutes and excess hair was carefully trimmed. The skin was either used in the 
permeation study “as-is” or was tape-stripped to create two impaired barriers: either half-
 5 
 
compromised (40 – 60% of SC removed) and fully-compromised (100% of SC removed) 
barrier.  
 Tape-stripping procedure [29]: A 10 x 10 cm2 area of skin was divided into 3 pieces. 
The first was not stripped and maintained a fully intact skin barrier; it provided a baseline 
reading of the TEWL (AquaFlux AF-102, Biox Systems Ltd., London, UK). After stabilization 
(requiring no more than 3 minutes) these control TEWL values (mean ± SD; n = 6) were 9.0 ± 
1.7 g.m-2.h-1. The second piece of skin was subjected to repeated application-removal of 
adhesive tapes (2 x 2 cm, Scotch Book Tape, 3M, St. Paul, MN) to progressively remove the SC 
and produce 100% barrier impairment. A 1.5 x 1.5 cm2 template affixed onto the skin ensured 
that SC was removed from the same location. Periodic measurement of the TEWL allowed the 
degree of barrier impairment to be quantified and achievement of full barrier impairment was 
indicated when no further increases in TEWL were observed upon continued tape stripping. 
The number of tapes required to produce a fully compromised skin ranged from 17 to 25; 
TEWL across fully-compromised was 153 ± 11 g.m-2.h-1 SC (n = 11). The third skin sample was 
again sequentially stripped as before but only until TEWL reached 40 – 60% of that of the fully 
perturbed barrier. Between 13 and 16 tape-strips were needed to produce half-compromised 
barriers across which TEWL was 76 ± 7.6 g.m-2.h-1 (n = 8). 
Table 1. Experiments performed to characterize midazolam passive and iontophoretic transdermal 
delivery across intact and compromised skin. 
Variable 
Donor 
 Current Intensity 
(mA) 
n Background  
solution1 
Midazolam 
(mM) pH 
pH 10 mM citrate + 30 mM NaCl 7.5 
3 
0.36 
4 
3.5 3 
4 4 
4.5 3 
Current 
intensity 
10 mM citrate 
+ 30 mM NaCl 7.5 3.5 
0.10 3 
0.20 3 
0.36 3 
Co-ion 
competition 
Water 15.5 3.6 0.36 5 
10 mM citrate  
15.0 3.5 0.36 
6 
10 mM citrate 
+ 30 mM NaCl 9 
10 mM citrate 
+ 90 mM NaCl 5 
Drug 
concentration 
10 mM citrate 
+ 30 mM NaCl 
1 
3.5 0.36 
3 
7.5 3 
15 9 
Skin barrier 
 
10 mM citrate 
+ 30 mM NaCl 15 3.5 
Passive 3 
0.36 5-8 
1 The citrate buffer comprised 7.4 mM citric acid monohydrate and 2.6 mM trisodium citrate dehydrate. pH changes 
at the end of all experiments did not exceed ±0.1 in citrate buffer and was no more than ±0.2 in water. 
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2.3 Iontophoresis set-up 
 Amber side-by-side two-compartment diffusion cells (active transport area = 0.71 cm2) 
were used. The experimental details are described elsewhere [29]. The skin separated the two 
chambers (3 mL) with the epidermal side facing the anode compartment. The solution in the 
receptor chamber was 154 mM sodium chloride (pH ~ 6) in all cases. For 30 minutes before 
starting the transport study, both compartments were filled with the drug vehicle to be used 
(but containing no drug), and with 154 mM sodium chloride, respectively. Both compartments 
were then emptied and refreshed, respectively, with the donor solution under study (which 
contained midazolam) and fresh receptor solution; both compartments were magnetically 
stirred (Multipoint-6 stirrer, Thermo Scientific Variomag, Cole-Parmer, London, UK) at 400 
rpm [29]. Direct constant current was applied (KEPCO 1000M, Flushing, NY, USA) for 6 hours 
to Ag/AgCl electrodes (anode in the donor solution, cathode in the receptor). Hourly samples 
(1 mL) of the receptor phase were withdrawn and replaced with fresh solution. Sink 
conditions were maintained in the receptor [30]. Following termination of iontophoresis, both 
donor and receptor solutions were refreshed (but now with no drug in the ‘donor’ solution) 
and the system was left for a further 15 hours at which point the receptor compartment was 
sampled and subsequently analyzed to determine the amount of midazolam released from 
the skin [29].  
Separate passive diffusion controls were also performed with samples taken every 2 hours for 
10 hours and a final sample withdrawn at 21 h. As above, each sample removed was replaced 
with 1 mL of fresh solution. The experimental conditions investigated are summarized in 
Table 1.  
2.4 Sample analysis 
 Midazolam was quantified by high-performance liquid chromatography with UV 
detection (220 nm) (Jasco UK Ltd, Dunmow, UK) including a PU-980 pump with an AS-1595 
autosampler, a UV-975 UV-VIS detector, and an Acclaim 120, C18 (150 x 4.6 mm, 5 µm) 
reversed-phase column (Dionex, UK) thermostatted at 25°C. The mobile phase was 50 mM 
phosphate buffer (adjusted to pH 2 with phosphoric acid) and acetonitrile (70:30) and was 
pumped through the system at 1 mL/min [29].  
2.5 Data analysis and statistics 
 Data analysis and interpretation used Graph Pad Prism V.5.00 (Graph Pad Software 
Inc., CA, USA) [29]. Data are presented as the mean ± standard deviation (SD), unless 
otherwise stated. Fluxes given are the amounts delivered during a certain time divided by the 
length of that period. Statistical significance was set at p < 0.05. Comparisons between 
different data sets of data were made using either a two-tailed unpaired t-test (for 2 groups) 
or a one-way ANOVA (for >2 groups) followed by Tukey’s post-test [29].  
 The transference number (TM+) of midazolam was computed according to Faraday’s 
law [31]: 
TM+ = {Jtotal·Z·F}/I   Equation (1) 
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where Jtotal is the total flux observed after 6 h iontophoresis, I is the current intensity applied, 
F is Faraday’s constant, and Z the absolute value of the valence of the drug ion. It was 
estimated from available literature [31, 33-34] that about 9% of midazolam might have been 
present as a divalent cation at pH 3.5. For the purposes of this work, however, and the 
calculation of TM+ using Equation (1), the valence of midazolam has been assumed to be +1. 
 3. Results 
3.1. Passive diffusion experiments across intact skin 
 The passive flux midazolam from a 15 mM solution of its hydrochloride salt (pH 3.5) 
through intact pig skin was 0.06 ± 0.01 nmol.h-1.cm-2 after 21 h.  
3.2. Iontophoretic experiments across intact skin 
3.2.1. Effect of donor pH on the iontophoretic flux of midazolam. 
Midazolam aqueous solubility is very low at pH values above 5 but increases significantly at 
acidic pH where the drug exists predominantly in its ionised form [30]. Iontophoresis 
experiments were therefore performed with donor solutions having pH values in the range of 
3.0 to 4.5 and the results are presented in Figure 1. 
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Figure 1: Midazolam iontophoretic transport (mean + or - SD, n = 3-4) as a function of donor solution pH. 
Midazolam was delivered from a 7.5 mM drug solution at a current of 0.36 mA. The flux values over each 
successive sampling period are plotted as a function of the time at the end of that corresponding sampling interval. 
Donor solutions with 7.5 mM midazolam at pH 4.5 were slightly cloudy but no observable 
precipitation occurred during the experiment. Iontophoretic transport increased with 
increasing pH; from the pH 4.5 donor solution, J6h = 18 ± 3.2 nmol.h-1, a value significantly 
higher (p < 0.05) than that with the pH 3 donor (6.0 ± 3.0 nmol.h-1). Fluxes from donors at pH 
3.5 and 4 fell between these extremes.  
 
3.2.2. Effect of current intensity on the iontophoretic flux of midazolam. 
Iontophoresis produced significant elevation of midazolam transport through intact 
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porcine skin relative to passive diffusion (Figure 2(a)). At the end of a 6-h experiment, in the 
absence of current, the flux was 14 ± 0.4 pmoles.h-1 compared to values of 2.4 ± 0.64 nmol.h-1, 
5.4 ± 0.57 nmol.h-1, and 10.4 ± 3.8 nmol.h-1 at currents of 0.1, 0.2 and 0.36 mA, respectively. 
Analysis of variance followed by Tukey’s post-test confirmed that all these flux values were 
significantly different from each other (p < 0.5). The flux of midazolam, furthermore, was 
linearly proportional (r2 = 0.88) to the applied current (Figure 2(b)). From the slope of this 
relationship, it was possible to calculate the drug’s transport number (TM+) for the 
experimental conditions used as 0.078 % ± 9.10-3 % (± SE). 
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Figure 2: Effect of current intensity on the iontophoretic flux of midazolam. (a) Drug flux (mean ± SD, n = 3) 
as a function of time and current intensity (passive indicates 0 mA). Fluxes are shown at the end of the 
corresponding sampling interval. (b) Midazolam flux at 6 hours as a function of applied current. The transference 
number of midazolam was estimated from the slope of the regression line ( J6h (nmoles.h-1) = 29.1 (±3.4) x Intensity 
(mA) - 0.26 (±0.7); p < 0.0001, r2 = 0.88) The donor solution in all experiments was 7.5 mM midazolam in 10 mM 
citrate buffer (pH 3.5) + 30 mM NaCl (37.8 mM sodium competing co-ion).  
 
3.2.3. Effects of co-ion competition and the molar fraction of midazolam. 
This series of experiments investigated how the iontophoretic delivery of midazolam 
depended on: (a) competing co-ion concentration (at fixed drug concentration), and (b) drug 
concentration (at fixed co-ion concentration). Figure 3 shows that, as expected, midazolam 
delivery was greatest when no competing co-ions were present (J6h = 62 ± 17 nmol.h-1).  In 
contrast, the smallest drug flux was found (J6h = 3.0 ± 0.39 nmol.h-1) when it was delivered 
from a 1 mM solution in a buffer containing ~37.8 mM Na+. There was no significant difference 
between midazolam iontophoresis from a 15.9 mM solution in water and a 15 mM solution in 
10 mM citrate (7.8 mM Na+) buffer. However, these fluxes were significantly greater (p < 0.05) 
than those from all the other four vehicles considered (Figure 3). As expected, the 
iontophoretic transport of midazolam was linearly dependent on the drug concentration (1, 
7.5 and 15 mM) in the 10 mM citrate + 30 mM NaCl (37.8 mM Na+) buffer (Fig.3). Figure 4 
illustrates graphically the linear increase in the deduced transference number of midazolam 
(TM+) as a function of the drug’s molar fraction in the donor (XM+). Linear regression of these 
data (r2 = 0.86) yielded a slope and intercept of 0.48 (±0.03) x 10-2 and 0.02 (±0.02) x 10-2, 
respectively.  
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Figure 3: Midazolam fluxes after 6 hours of iontophoresis at 0.36 mA (mean + SD, n = 3-9) as a function of 
drug and principal competing co-ion (Na+) concentrations (see Table 1).  
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Figure 4: Deduced transference numbers of midazolam (mean ± SD, n = 3-9) at 6 hours of iontophoresis as a 
function of the drug’s molar fraction in the donor vehicle. A simple linear regression of the data is shown. 
 
3.3. Passive and iontophoretic experiments across compromised skin 
Skin barrier impairment led to significant increases in passive fluxes of the drug (Figure 
5).  After 6 hours exposure, the rate of midazolam transport across intact skin was 0.03 ± 0.01 
nmol.h-1, compared to 1.9 ± 0.3 nmol.h-1 and 33 ± 8.4 nmol.h-1 across half-compromised and 
fully-compromised skin barriers, respectively (i.e., a 1000-fold enhancement in flux when the 
SC had been completely removed). With iontophoresis at 0.36 mA (Figure 5), the drug fluxes 
across intact and half-compromised skin barriers were not significantly different (24 ± 5.7 and 
27 ± 14 nmol.h-1, respectively. However, the iontophoretic flux was significantly greater (128 
± 46 nmol.h-1) across a fully compromised barrier. Figure 6 illustrates the empirical (and 
apparently exponential) relationship between the individual passive and iontophoretic fluxes 
of midazolam and the TEWL values of the corresponding skin samples. Finally, it is worth 
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noting that iontophoresis delivered significantly more (p < 0.02) midazolam than passive 
diffusion across intact, half- and compromised skin. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Passive (yellow bars) and iontophoretic (green bars) fluxes at 6 hours of midazolam (mean + SD; n 
= 3-9) across intact, half-compromised and fully-compromised skin barriers. Note the use of a logarithmic scale for 
the flux values. 
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Figure 6: Dependence of individual midazolam fluxes on the TEWL values of the corresponding skin samples. 
Open symbols represent the passive diffusion (P) data; the filled symbols are the iontophoresis (I) results. Intact, 
half- and fully-compromised skin barriers are indicated by diamonds, triangles and circles, respectively. The lines 
through the points are empirical, exponential fits of the data: passive diffusion, J6h = 0.14 x exp(0.04 x TEWL) (n = 
9); iontophoresis (n=16, r2 = 0.80 : J6h = 11.6 x exp(0.02 x TEWL) (n = 16). 
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Finally, perturbation of the skin barrier resulted in greater delivery of midazolam to the 
receptor compartment in the post-iontophoresis period as well (Table 2).  
Table 2. Cumulative amount of midazolam (in nanomoles) (a) delivered through intact and 
compromised skin during 6 hours of iontophoresis at 0.36 mA, and (b) released passively from the 
skin during 15 h post-iontophoresis (mean ± SD, n = 3-9).  
Experimental period Intact skin Half-compromised skin Fully compromised skin 
Iontophoresis for 6 hours 101 ± 28 91 ± 57 485 ± 192 
Passively released over 15 h 
post-iontophoresis 33 ± 6.1 104 ± 11 276 ± 42 
 
 
4. Discussion 
Few studies have characterized the passive transdermal delivery of midazolam. Touitou et al. 
[34] measured a flux of 9.5 nmol.h-1.cm-2 following application of midazolam maleate (at 11.3 
mM in unbuffered water) to hairless mouse skin in vitro. Balaguer-Fernández et al. [35] 
reported delivery at 3 nmol.h-1.cm-2 after an 8-hour treatment of excised human skin with 
midazolam hydrochloride (2.76 mM) from an unbuffered solution (initially at pH 5.5). Direct 
comparison with the passive flux reported in this study (0.06 ± 0.01 nmol.h-1.cm-2) is difficult 
because of the different skin models used and the inconsistency in the composition and 
buffering of the applied formulations. However, in agreement with Balaguer-Fernández et al. 
[35], iontophoresis was shown to significantly enhance midazolam delivery relative to its 
passive diffusion. 
A first series of iontophoretic experiments investigated how the composition of the donor 
vehicle (pH, drug concentration and background electrolyte) and the intensity of current 
applied [31, 36] modified the iontophoretic transport of midazolam. The observed increase in 
the delivery of the drug with increasing pH requires consideration of a number of factors. 
First, at the lower end of the pH range, the drug exists in a predominantly positively-charged 
form, with about 20% having a charge of +2, the remainder +1 [30, 32-33]. These cations are 
expected to differ in their iontophoretic transport efficiency [37] but exactly to what extent, in 
a quantitative sense, is unknown. Second, the lower the pH, the greater concentration of H3O+ 
ions in the donor solution. These highly mobile cations [38], even at sub-millimolar 
concentrations, can nevertheless compete effectively with the positively-charged drug to carry 
current across the skin (i.e., decreasing the transference number of midazolam with 
decreasing pH) [39,40]. Third, porcine skin has been shown to have an isoelectric point of ~4.4 
[41]. This means, at pH > 4.4, that the skin supports a net negative charge and is therefore 
cation-permselective under these conditions. In addition to favouring cation electrotransport, 
the net negative charge on the membrane means that the imposition of an electric field across 
the skin indices an electroosmotic flow of solvent in the direction of counter-ion movement, 
further enhancing the flux of midazolam. In contrast, at pH 3, with the elevation in H3O+ 
concentration, the skin now assumes a net positive charge, becoming anion-permselective, and 
the direction of electroosmotic flow is reversed – all factors now working against the 
iontophoretic delivery of a cationic drug from the anode. 
 12 
 
From the results obtained (Figure 1), it is clear for midazolam that the advantages of a 
donor solution pH at, or slightly above, the pI of the skin outweigh the greater degree of 
ionization of the drug at lower pH values; similar observations have been made for other 
drugs, including apomorphine, rotigotine and 5-OH-DPAT [39,42-43]. That having been said, 
it must be emphasised that other biopharmaceutical factors also play a role in formulation 
optimisation. The cloudiness of a 7.5 mM midazolam solution at pH 4.5 suggests that it is at 
(or very near) saturation and therefore not ideal from a stability point of view. There is a trade-
off to be made, therefore, between donor formulation pH and drug solubility (and, perhaps, 
stability) in terms of developing an effective formulation for iontophoretic delivery. In 
addition, the relative contributions of electro-migration and electro-osmosis to the total 
iontophoretic transport must be considered [31, 36, 40]. For example, in an earlier study, a pH 
5.5 donor solution of 2.8 mM midazolam was selected to ensure a beneficial electroosmotic 
contribution and fluxes in the range of 12.2 to 21.3 nmoles.h-1.mA-1 were observed [35]. In this 
work, the strategy adopted was to optimize electro-migration by increasing the drug 
concentration and mole fraction: iontophoresis of 7.5 mM midazolam from a donor vehicle at 
pH 4.5 donor produced a flux of 49 (±8.9) nmoles.h-1.mA-1 flux. Based on these results, all 
subsequent experiments were performed with pH 3.5 donors as this would ensure complete 
solubility of midazolam at higher drug concentrations. Because this pH is slightly lower than 
the range (4.0-5.9) of the “so-called” adult skin pH, its tolerability on premature skin and 
impact on barrier maturation should be assessed (also bearing in mind that skin acidification 
is essential for barrier maturation) [44, 45].  
 The data in Figure 2 re-affirm the value of iontophoresis as a method to control drug 
delivery and shows that dosing can be sensitively adjusted in a productive fashion by the 
applied current [ 31, 36, 46-48]. The potential of personalization of therapy is therefore evident. 
It is noteworthy, however, that the transference number of the drug deduced from these 
experiments suggests that only 0.08% of the current is carried across the skin by midazolam 
cations; the vast majority is transported by H3O+, Na+ and Cl- (the latter moving in the cathode-
to-anode direction, of course). Despite the very significant enhancement of drug flux achieved 
by iontophoresis – relative to passive diffusion – the efficiency of the approach is, at best, 
modest even for a typical small drug such as midazolam. 
 As previously demonstrated for several drugs [29, 49-52], further manipulation and, 
eventually, maximization of iontophoretic delivery can be achieved by varying the mole 
fraction (relative to other cations present) of the active compound in the donor solution. The 
results in Figures 3 and 4 demonstrate that midazolam transport was directly proportional to 
its mole fraction in the anodal solution and reached its greatest value when the drug was 
formulated as an aqueous solution, when a transference number of 0.46% was attained. Molar 
fraction, rather than nominal concentration, determined the efficiency of midazolam 
iontophoresis - see, for example, when 7.5 mM/XM+ = 0.16 and 15 mM/XM+ = 0.13 in Figure 4. 
This is another important consideration in formulating iontophoretic vehicles. While such an 
observation conforms nicely with our theoretical understanding, the unbuffered formulation 
of a drug in water alone may be practically unacceptable for a number of reasons, such as 
stability, solubility and electrochemistry (e.g., having sufficient Cl- present to satisfy the 
requirements of the Ag(s) + Cl-(aq) -> AgCl(s) anode reaction for the duration of treatment at 
the chosen current intensity). 
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 A further series of experiments, the results of which are presented in Figures 5 and 6 
and Table 2, aimed to examine whether iontophoresis might provide a safe and effective 
approach to deliver midazolam to paediatric patients and, in particular, to premature 
neonates, the skin barrier function of whom represents a “moving target” after birth [16-24]. 
To experimentally model completely and partially compromised skin barriers, the stratum 
corneum (SC) was progressively removed by adhesive tape-stripping and the extent of 
perturbation was quantified using measurements of transepidermal water loss (TEWL).  
TEWL can be as high as 60-90 g.m-2.h-1 in a 25-week gestational age (GA) neonate and 
decreases exponentially to reach adult values at 34-37 weeks GA [12, 51-52]. Thus, our data 
with the half-compromised skin is representative of a 25-week GA premature newborn. TEWL 
matures rapidly with postnatal age [22]; for example, the TEWL in 78 neonates achieved 
maturation values 2 to 3 weeks after birth and independently of their GA (26-41 weeks). The 
approach used in our work has been previously described [28, 53-59] and, as before [24, 54, 
58, 59], an empirical, exponential relationship between both passive and iontophoretic drug 
fluxes and the degree of skin barrier competency (assessed by TEWL) was found (Figure 6). 
The results in Figure 5 show that iontophoresis was clearly controlling drug delivery across 
intact and half-compromised skin, the most relevant range of barrier competence. Thus, 
importantly, it was found that iontophoresis can maintain control of delivery at least up to the 
point where the skin barrier has been reduced to 50% competency. When the SC is completely 
absent, the iontophoretic control is unable to “keep up with” a large passive diffusion 
contribution (as indicated by the significantly greater flux observed across a fully 
compromised barrier). Table 2 also reveals an additional factor to take into consideration. The 
‘release’ of midazolam from the differentially compromised skin barriers indicates that this 
relatively lipophilic drug (log P = 4.3) is able to accumulate in the skin during iontophoresis 
(an observation possibly linked to the altered direction of conventional electroosmotic flow at 
lower pH values [60]). As a result, there will be continued delivery of drug occurring after 
iontophoresis has been terminated, a feature to bear in mind if chronic, repeated dosing is 
envisaged with rotation of the treated skin sites. Taken together, and from a practical point of 
view, the results reported – assuming their validation in vivo – suggest that iontophoresis of 
midazolam is perhaps best suited for term and premature neonates with at least a half-
competent skin barrier, such that drug delivery is rate-controlled by the current applied (and 
with due attention to continued input of the drug post-application. 
 The key question addressed by this aspect of the study, of course, is whether 
iontophoretic delivery of midazolam may be a viable treatment option for paediatric patients. 
Assuming that the in vitro fluxes measured in this work are duplicated in vivo, the target input 
rates indicated in the British National Formulary for Children are (a) 92-184 nmol h-1 kg-1 for 
infants born from 32 weeks of gestational age (i.e., approximately 8 weeks premature) to 5 
months of age, and (b) 92-368 nmol h-1 kg-1 for children aged from 6 months to 11 years. Based 
on these numbers, and the availability of an iontophoretic device that delivers the midazolam 
fluxes achieved across intact and half-compromised skin barriers reported in Figure 5, a 
simple calculation reveals that an effective treatment should be achievable with simple gel 
electrodes of a few square centimetres in size per kilogram of infant body weight [12, 31, 61]. 
For older infants and young children, however, the dimensions of the electrode ‘patches’ 
becomes progressively impractical with increasing age (and required dose). Assuming the 
efficacy of iontophoresis was established, safety becomes the next key consideration, i.e., 
whether the technique will be tolerated by the targeted population. Safety was beyond the 
 14 
 
scope of this exploratory in vitro study. However, experience with the marketed GlucoWatch 
Biographer® and LidoSite® devices, and from other reports [12-14], suggest that iontophoresis 
is similarly well-tolerated by children with mature skin barrier function as it is by adults. To 
the authors knowledge, there is no published data concerning iontophoresis in the premature 
population; of course, such studies would be essential to pursue further development of the 
approach described here. 
 
5. Conclusions 
 In vitro characterisation of midazolam iontophoresis across the skin has identified the 
critical factors to optimise for flux maximization and has demonstrated the method’s ability 
to control drug input into a patient when the skin barrier is compromised. Based on these 
findings, it has then been possible to postulate that an iontophoretic device may be capable of 
delivering midazolam at therapeutic doses to premature infants and neonates. 
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Supplementary Material 
 
 
 
 
 
 
 
 
 
 
Midazolam exists in a pH-dependant equilibrium with an open-ring structure in acidic 
conditions (29,30,32,33). 
 
